Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study

Affiliations

¹ Stanford Cancer Center, Stanford, CA, United States.
² Stanford University School of Medicine, Stanford, CA, United States.
³ Hôpital Saint Louis, APHP, Inserm U976, Université de Paris, Paris, France.
⁴ INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; University of Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire d'Immunologie-Histocompatibilité, Hôpital Saint Louis, AP-HP, Paris, France.
⁵ Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, United States.
⁶ Kyowa Kirin, Inc., Bedminster, NJ, United States.

Youn H Kim et al. Eur J Cancer. 2021 Oct.

. 2021 Oct:156 Suppl 1:S48-S49.

doi: 10.1016/S0959-8049(21)00715-2.

¹ Stanford Cancer Center, Stanford, CA, United States.
² Stanford University School of Medicine, Stanford, CA, United States.
³ Hôpital Saint Louis, APHP, Inserm U976, Université de Paris, Paris, France.
⁴ INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; University of Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire d'Immunologie-Histocompatibilité, Hôpital Saint Louis, AP-HP, Paris, France.
⁵ Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, United States.
⁶ Kyowa Kirin, Inc., Bedminster, NJ, United States.